AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2012
May 3, 2012
30583_dirs_2012-05-03_1fbebebb-a987-4d4f-b1e3-4d598f48cdb6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2012-04-30
Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-04-30 | Common Stock | A | 1098 | $19.346 | Acquired | 113191 | Direct |
| 2012-05-01 | Common Stock | M | 20000 | $9.86 | Acquired | 133191 | Direct |
| 2012-05-01 | Common Stock | S | 20000 | $34.996 | Disposed | 113191 | Direct |
| 2012-05-02 | Common Stock | M | 10000 | $9.86 | Acquired | 123191 | Direct |
| 2012-05-02 | Common Stock | S | 10000 | $35.72 | Disposed | 113191 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-05-01 | Stock Option (right to buy) | $9.86 | M | 20000 | Disposed | 2015-11-10 | Common Stock (20000) | Direct |
| 2012-05-02 | Stock Option (right to buy) | $9.86 | M | 10000 | Disposed | 2015-11-10 | Common Stock (10000) | Direct |
Footnotes
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2011 to April 30, 2012.
F2: Transaction made pursuant to a Rule 10b5-1 Trading plan executed on April 27, 2012.
F3: The price in Column 4 is a weighted average price. The prices actually received ranged from $34.465 to $35.31. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price in Column 4 is a weighted average price. The prices actually received ranged from $34.755 to $36.32. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Original option grant vested 1/3 each on May 11, 2006, May 11, 2007, and May 11, 2008.